IDeate-Lung01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Apr 1, 2023 → Oct 16, 2026

Cited window

Apr 27, 2023 → Oct 8, 2026

Retrieved

Oct 19, 2026

Title

A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

Registry

NCT05280470

Study IDs

DS7300-127 · 2022-000503-13 · 2041220019 (jRCT)

Sponsor

Daiichi Sankyo

Collaborators

Merck Sharp & Dohme LLC

Design

Phase 2 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

187 actual

Start

2022-03-09 actual

Primary completion

2025-03-03 actual

Primary endpoint

Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 3 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –212 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition do not represent all HCP discussion, and repeated posts or shared presentations cannot be counted as independent clinician agreement.
• –Searches emphasized trial identifiers, drug names and selected relapsed-disease terms. Unnamed references and transcription variants may be absent; eight additional sources were not read, and several passages in included discussions were not fully evaluated.
• –Some participants could not be identified reliably, and one recording relied on its available transcript. Anonymous views have not been assigned to faculty from a program listing, a host's address or an account identifier.
• –The unidentified long-form X author's clinical role is unknown. The author's regulatory and comparative arguments should not be treated as physician consensus or an FDA explanation.
• –The discussion spans different studies, analyses and dates. Earlier Phase I/II findings, IDeate-Lung01 interim and later reports, and IDeate-Lung02 plans cannot be combined as one dataset or used to infer a change of mind.
• –Reported efficacy and safety values differ across sources. These differences were preserved rather than reconciled, pooled or converted into treatment comparisons; Ergün's post does not specify an OS unit.
• –The complete protocol and an exact approved I-DXd label were not available. Source reports of regulatory developments, trial management and anticipated access do not establish current prescribing instructions or availability.
• –The eligibility described by Hann included ECOG 0–1 and treated or untreated asymptomatic brain metastases. The discussion does not establish applicability to poorer performance status or symptomatic CNS disease.
• –A case-discussion turn used 1 mg/kg for tarlatamab and a later turn used 1 mg. These were tentative, patient-specific statements, not reconciled dosing guidance.

How reports are built and checked: Methods.

Last checked for new commentary Oct 20, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.